Tagged with OBI

India As one of the world’s a leading pharma manufacturers, India supplies about 20 percent of the global pharmaceuticals demand in terms of volume, yet the industry remains plagued with quality compliance issues. After Sun Pharma, Aurobindo and Zydus found themselves on the FDA’s radar earlier this year, two more Indian…

India Top stories from Indian pharma including Dr Reddy’s move to US online platforms, Aspen/Serum Institute’s vaccine deal for Africa, Aurobindo’s USD 37.7 million investment in subsidiary CuraTeQ and Biocon’s FDA troubles.   Indian pharma market growth in August 12.1 percent (The Economic Times India) According to a study from the…

South Korea ExoCoBio’s CEO, Byong Seung Cho, went from biotech venture capital to setting up ExoCoBio, a company whose core technology is based on adipose stem-cell derived exosomes for regenerative medicine and medical aesthetics. He walks us through ExoCoBio’s exosome-based finished product line as well as its promising preclinical findings not just…

Croatia With the start of construction on a EUR 100 million biotech production plant near the Croatian capital Zagreb, Pfizer continues its investment in the country. The creation of the plant is the result of a partnership with the Swedish company specialised in rare diseases, Sobi, and Pfizer-backed CDMO Pfizer CentreOne…

Spain Sobi’s VP and general manager for Spain and Portugal, Pablo De Mora, comments on his experience during the pandemic, the Swedish company’s haematology and immunology portfolio, including its EMA-approved COVID-19 treatment, and the reimbursement challenges faced by rare disease players in Spain. Moreover, De Mora highlights Sobi’s vast clinical trials…

Italy Speaking recently to PharmaBoardoom, Assobiotec’s Leonardo Vingiani introduced the key dynamics shaping the Italian biotech industry today and the issues it still has to overcome to become truly globally competitive.   Strong Fundamentals The association’s latest reporting shows that there are 751 active biotech firms in Italy, with a turnover…

Italy Assobiotec’s Leonardo Vingiani introduces the key trends shaping the Italian biotech ecosystem today, the steps that the country’s government have taken to foster life sciences innovation, and the areas in which Italian biotechs truly excel globally.   Italy and its researchers have created a good environment for science. However, the…

China The latest from Chinese pharma, including a setback for CanSinoBIO’s Canadian COVID-19 vaccine trial, Bayer’s new Beijing manufacturing plant, and biotech Antengene’s potential USD 200 million IPO in Hong Kong.   Canada scraps COVID-19 vaccine trial with Chinese CanSinoBIO https://globalnews.ca/news/7302041/canada-china-covid-19-vaccine-trials-abandoned-national-research-council/ Canada has decided to cancel a coronavirus vaccine development agreement…

China Chinese biotech CanSinoBIO is racing against the clock to have a COVID-19 vaccine ready to begin production in early 2021. The firm’s senior VP of International Business Pierre Morgon reflects on CanSinoBIO’s progress thus far and a timeline of what we can realistically expect if and when Chinese authorities give…

Korea Genome & Company, with a market cap of USD 280 million, is the highest valued microbiome company worldwide. Dr Jisoo Pae, its co-founder and CEO, sat down with PharmaBoardroom to shed light on the company’s origins, its collaboration with Big Pharma, and the ease of gaining capital investment for a…

China Pierre A Morgon, SVP International Business for CanSino Biotechnology (CanSinoBIO) – a Chinese vaccine biotech developing one of the frontrunner COVID-19 vaccine candidates – shares how his extensive international career brought him to CanSinoBIO, the deeply-rooted public health orientation of the vaccines sector, the complex realities of developing and deploying…

China Mike Chen, president and CEO of ACROBiosystems, shares his global success as a manufacturer of recombinant proteins supporting biologics R&D and how he hopes to expand his business to eventually set up a multifaceted platform for MNCs and biotechs.   By having a manufacturing facility in the USA or Europe,…